In the aftermath of a fire that occurred at the WIPO offices on October 27, the patent documents that had been due on this day were not entered into the public WIPO database until early November. We will cover any remarkable life science documents that were to to be published in this batch in out next monthly review. - Even for the October 6-20 period we can present a selection of 9 PCT publicatio...

Last week I talked to the CEO of a small, innovative startup pharma development company; he had some interesting facts to relate. Specifically, he told me about the latest one-to-one meeting series he had.It is always the same time-honored thing with such events: you pay a lump sum, in return for a guarantee that the organizer will broker X time slots for private talks with potential customers or...

Our monthly life science patent commentaries have quickly achieved top ranks in the access statistics for our blog. They have also not gone unnoticed elsewhere in the science publishing environment. I am happy to tell that starting with 2012, even more detailed pharma patent analyses will be published in a to-be- launched specialist journal (details to follow later). But don't worry, this doesn't...

The International Patent Office has not been idle during this summer, and neither were we. Once again, ten international patent applications are brought to the fore: for childhood epilepsy, obesity, cancer, muscle wasting, Parkinson's and Alzheimer's disease, and for laser-triggered ocular drug delivery. PLEASE CITE AS : Mucke HAM. Patent Highlights for August 2011. Published online on the H.M. Ph...

Hermann Mucke,H.M. Pharma Consultancy's CEO I would like to invite you to follow me on the new social web service, Google plus. It might look (and sometimes, also feel) like Facebook, and it is still in beta; but it works well already, and you can already see what makes it different from Facebook. G+ is built around Circles to which you can post, and your posts are restricted to these Circles...

Eight months into the existence of "Drug Repurposing - Reprofiling - Repositioning," a little bit of analysis would seem to be in order. An active online community has formed, and its still growing -- of course not as much as it did initially, but we still run an average of 15-20 new members per month. January and May 2011 were strongest so far, with 43 and 32 people joining.Membership is at 232, ...

H.M. Pharma Consultancy is happy to announce the launch of its newest technology and market report, again published and marketed by our longtime partners, Insight Pharma Reports: "Engineering Next-Generation Therapeutic Proteins: Trends and Markets to 2020" Table of contents and ordering details here Read the Insight Pharma Reports press release here.The pharmaceutical industry's current di...

This month's reviewed patents are rife with claims indicating drug repurposing opportunities: the antidiabetic glibenclamide for cerebral malaria; various prenyltransferase inhibitors for hepatitis delta infection; and the antidepressant amitryptiline for lung cancer. There are plenty new compounds as well: carbolines for hearing loss and tinnitus,STEP inhibitors for cognitive disturbances esp. in...

The world of the pharmaceutical industry is a world of science, manufacturing, and doing studies. It also is a world of patents. A good part of H. M. Pharma Consultancy's business is rooted just in this fact: we help small and/or virtual companies with their strategic patenting, we draft patent applications, we try to find gaps in intellectual property and we try to avoid them. With new molecules,...

YES! -- Did it again. Here are 9 international applications for life science patents, published in June 2011, that we find remarkable. Vision loss, cardiomyocyte regeneration, hepatic encephalopathy, and new targets for Alzheimer's disease, influenza, and cancer are our subjects for this month. As always, we link chemical compounds to ChemSpider, genes and peer review literature to the respective...